---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-049148"
form_type: "8-K"
ticker: "CNTN"
cik: "0001861657"
company_name: "Canton Strategic Holdings, Inc."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:45:55.438523+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tharimmune raises $2.02M in private placement for TH104 development

## Summary
- Gross proceeds of ~$2.02M from issuance of 961,446 common shares (or equivalents) and warrants for 480,723 shares at $2.10 per unit.
- Warrants exercisable at $2.031/share, starting 6 months after issuance, expiring in 5.5 years.
- Placement led by Gravitas Capital and SDS Capital Group; President Street Global as exclusive agent.
- Net proceeds to fund clinical development of TH104 (pruritus in PBC) and working capital.
- Closing expected on or about December 9, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001493152-24-049148
- form_type: 8-K
- ticker: CNTN
- cik: 0001861657
- company_name: Canton Strategic Holdings, Inc.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861657/000149315224049148/0001493152-24-049148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861657/000149315224049148/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-049148
- JSON: https://secwatch.observer/filing/0001493152-24-049148.json
- Plain text: https://secwatch.observer/filing/0001493152-24-049148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.